[The role of lipid metabolism in the prevention of coronary heart disease].
Prevention of cardiovascular disease should be considered as a continuum from low to high risk: those at the highest risk are patients with clinically manifest cardiovascular disease, followed by subjects without known cardiovascular disease at different levels of risk from high to low. Today there is clear evidence that an independent relationship exists between plasma LDL cholesterol levels and the risk for coronary heart disease. The relationship between other plasma lipoproteins and atherosclerosis is more complex. The threshold for individuals requiring LDL cholesterol reduction is determined by epidemiological data, randomized controlled trials, and economic considerations. Patients with familial dyslipidemia suffer early coronary morbidity and mortality. For these patients, consequent lowering of LDL cholesterol should be the primary objective. For patients with established coronary heart disease or other atherosclerotic disease and for those with diabetes, there is significant evidence that reducing LDL cholesterol, irrespective of the initial values, reduces the risk of further coronary events, stroke, and total mortality. For asymptomatic individuals, the treatment of plasma lipids should be based on their absolute coronary risk, including other cardiovascular risk factors. The goals for plasma LDL cholesterol have been set in national and international recommendations. The goals for LDL cholesterol in patients with low, moderate and high coronary risk are <160, <130 and 100 mg/dl, respectively. In some very high risk patients LDL level markedly below 100 mg/dl should be aimed at. HDL cholesterol and triglyceride measurements should be used to identify individuals at high multifactorial risk of cardiovascular disease and used as additional considerations in the selection of lifestyle and drug interventions.
Mathes
P
P
Rehabilitationszentrum München, Carl-Wery-Str. 26, 81739 München, Germany.
Thiery
J
J
D008078:Cholesterol, LDL / Q000097:blood*; D002986:Clinical Trials as Topic; D015897:Comorbidity; D003327:Coronary Disease / Q000097:blood / Q000453:epidemiology* / Q000517:prevention & control*; D004035:Diet Therapy / Q000379:methods; D005858:Germany / Q000453:epidemiology; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000401:mortality* / Q000517:prevention & control*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D050356:Lipid Metabolism; D015995:Prevalence; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D040242:Risk Reduction Behavior; D016896:Treatment Outcome
D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents